marked.bio

pan-RAF inhibitor · small molecule

belvarafenib

1 active trials across 3 of our biomarkers, targeting RAF. Not approved for any biomarker on marked.bio yet.

Also known as HM95573.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 3 Phase 2
KRAS G12C 0 2 –
KRAS G12D 0 2 –

Trials

1 of 3 trials shown

  1. Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors

    Recruiting Phase 2 Samsung Medical Center Started 2026Primary completion 2028-06 NCT07688356

    belvarafenib

    Documented BRAF mutation, including point mutations (e.g., V600E) or BRAF fusion mutations.

    BRAF V600EPrimary Brain Tumor, Metastatic Brain Tumor